Aprea Therapeutics (NASDAQ:APRE – Get Free Report) and Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.
Risk & Volatility
Aprea Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.07, suggesting that its share price is 407% more volatile than the S&P 500.
Earnings & Valuation
This table compares Aprea Therapeutics and Aptevo Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aprea Therapeutics | $580,000.00 | 27.36 | -$14.29 million | ($2.81) | -1.04 |
| Aptevo Therapeutics | $3.11 million | 1.60 | -$17.41 million | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Aprea Therapeutics and Aptevo Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aprea Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Aptevo Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Aprea Therapeutics presently has a consensus price target of $15.50, indicating a potential upside of 430.31%. Aptevo Therapeutics has a consensus price target of $8.00, indicating a potential upside of 2,871.77%. Given Aptevo Therapeutics’ higher possible upside, analysts plainly believe Aptevo Therapeutics is more favorable than Aprea Therapeutics.
Institutional and Insider Ownership
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 12.8% of Aprea Therapeutics shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Aprea Therapeutics and Aptevo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aprea Therapeutics | -1,029.50% | -57.86% | -47.94% |
| Aptevo Therapeutics | N/A | -353.04% | -132.42% |
Summary
Aprea Therapeutics beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
About Aptevo Therapeutics
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
